Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmAust’s preliminary test results have indicated a 95 per cent suppression rate of COVID-19 virus particles.
  • The two drugs tested both work to slow the infectious spread of the virus
  • The next stage for PAA is phase one human trials of the two treatments, though no start date has been set
  • PharmAust shares are up 22.7 per cent on the news, trading at 13.5 cents per share

Oncology company PharmAust (PAA) has announced recent testing of two drugs has shown they both succesfully suppressed the infectivity of COVID-19 virus particles by up to 95 per cent.

Repeat experiments, undertaken by the Walter and Eliza Hall Institute of Medical Research in Melbourne, looked at the effects of monepantel (MPL) and monepantel sulfone (MPLS) used on cells infected with COVID-19.

The results show a significant reduction in the spread of the virus.

Walter and Eliza Hall Institute researcher Professor Marc Pellegrini said the results were very exciting.

“Demonstrating twice that infectivity of SARS-CoV-2 virus particles can be suppressed by up to approximately 95 per cent in cell cultures is a remarkable outcome,” he said.

“We intend to continue collaborating with PharmAust with preclinical experimentation to support their progress,” he added.

PharmAust will now prepare materials for clinicians, discussing a trial of the drugs in a small number of human patients infected with COVID-19.

However, no date has been set for when the trial may begin.

The company also said it will work with the Walter and Eliza Hall Institute to further compare the MPL and MPLS with other anti-viral drugs authorised by the FDA for emergency COVID-19 treatment, such as remdesivir.

The remdesivir drug has origins as an Ebola treatment, while MPL was first tested as a cancer treatment.

As of today, more than 7000 cases of COVID-19 have been recorded in Australia, including 102 deaths.

Meanwhile, the latest data from the World Health Organisation shows the global number of infected people has surpassed eight million, with over 440,000 deaths.

PharmAust shares are selling at 13.5 cents each, a jump of 22.7 per cent.

PAA by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.